Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:50 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 539524 | NSE: LALPATHLAB

Dr Lal Pathlabs Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,133.31Overvalued by 14.40%vs CMP ₹1,324.00

P/E (40.4) × ROE (24.3%) × BV (₹143.00) × DY (0.91%)

₹532.25Overvalued by 59.80%vs CMP ₹1,324.00
MoS: -148.8% (Negative)Confidence: 63/100 (Moderate)Models: 1 Fair, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,233.0922%Fair (-6.9%)
Graham NumberEarnings₹318.6116%Over (-75.9%)
Earnings PowerEarnings₹171.5213%Over (-87%)
DCFCash Flow₹494.5913%Over (-62.6%)
Net Asset ValueAssets₹142.567%Over (-89.2%)
EV/EBITDAEnterprise₹592.459%Over (-55.3%)
Earnings YieldEarnings₹315.507%Over (-76.2%)
ROCE CapitalReturns₹374.379%Over (-71.7%)
Revenue MultipleRevenue₹220.385%Over (-83.4%)
Consensus (9 models)₹532.25100%Overvalued
Key Drivers: Wide model spread (₹143–₹1,233) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 8.8%

*Investments are subject to market risks

Investment Snapshot

72
Dr Lal Pathlabs Ltd scores 72/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health88/100 · Strong
ROCE 28.9% ExcellentROE 24.3% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money45/100 · Moderate
FII holding down -3.61% (6mo) SellingDII holding up 3.41% MF buyingPromoter holding at 53.2% Stable
Earnings Quality50/100 · Moderate
OPM stable around 28% Steady
Quarterly Momentum80/100 · Strong
Revenue (4Q): +11% YoY GrowingProfit (4Q): +26% YoY Strong
Industry Rank85/100 · Strong
P/E 40.4 vs industry 75.2 Cheaper than peersROCE 28.9% vs industry 14.7% Above peersROE 24.3% vs industry 13.9% Above peers3Y sales CAGR: 6% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:50 am

Market Cap 22,178 Cr.
Current Price 1,324
Intrinsic Value₹532.25
High / Low 1,771/1,176
Stock P/E40.4
Book Value 143
Dividend Yield0.91 %
ROCE28.9 %
ROE24.3 %
Face Value 10.0
PEG Ratio4.59

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Dr Lal Pathlabs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Dr Lal Pathlabs Ltd 22,178 Cr. 1,324 1,771/1,17640.4 1430.91 %28.9 %24.3 % 10.0
Aster DM Healthcare Ltd 35,559 Cr. 688 732/45098.7 87.50.73 %10.7 %8.26 % 10.0
Metropolis Healthcare Ltd 8,796 Cr. 424 566/32950.3 69.10.24 %14.7 %11.5 % 2.00
Healthcare Global Enterprises Ltd 7,990 Cr. 535 800/498294 61.70.00 %8.56 %5.14 % 10.0
Thyrocare Technologies Ltd 5,762 Cr. 362 538/22043.8 32.41.93 %26.5 %17.4 % 10.0
Industry Average26,819.31 Cr611.5975.1783.710.36%14.71%13.91%9.04

All Competitor Stocks of Dr Lal Pathlabs Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 489491541601539545602660597603670731660
Expenses 376375395424398401432458443434478506480
Operating Profit 113116146178141145170202154169192224179
OPM % 23%24%27%30%26%27%28%31%26%28%29%31%27%
Other Income 101414181818212225262825-6
Interest 9988776655557
Depreciation 38383536363735353636354042
Profit before tax 7683118152116120150183138153181204124
Tax % 30%32%29%27%29%28%28%29%29%-1%26%25%26%
Net Profit 54578411182861081319815613415291
EPS in Rs 3.173.404.956.554.875.066.377.735.789.267.908.995.40

Last Updated: February 6, 2026, 3:46 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 23, 2026, 10:46 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 5586607919121,0571,2031,3301,5812,0872,0172,2272,4612,663
Expenses 4195045826757939109871,1451,5261,5271,6171,7641,898
Operating Profit 139156210238264294344436561490609698765
OPM % 25%24%26%26%25%24%26%28%27%24%27%28%29%
Other Income 8122027314655515242699173
Interest 00011115163038292222
Depreciation 2728282833387377108150144142154
Profit before tax 119140201237261301310394475344505625662
Tax % 33%31%34%34%34%33%27%25%26%30%28%21%
Net Profit 8096133156172200228296350241362492533
EPS in Rs 74.388.757.999.3110.2411.9513.5517.4920.6914.3321.4229.1431.55
Dividend Payout % 7%9%15%16%22%25%44%57%29%42%56%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)20.00%38.54%17.29%10.26%16.28%14.00%29.82%18.24%-31.14%50.21%35.91%
Change in YoY Net Profit Growth (%)0.00%18.54%-21.25%-7.04%6.02%-2.28%15.82%-11.58%-49.39%81.35%-14.30%

Dr Lal Pathlabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:14%
5 Years:13%
3 Years:6%
TTM:11%
Compounded Profit Growth
10 Years:18%
5 Years:17%
3 Years:12%
TTM:35%
Stock Price CAGR
10 Years:%
5 Years:12%
3 Years:11%
1 Year:-3%
Return on Equity
10 Years:23%
5 Years:22%
3 Years:20%
Last Year:24%

Last Updated: September 5, 2025, 3:10 am

Balance Sheet

Last Updated: December 10, 2025, 2:36 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 54558383838383838383838484
Reserves 1512604255127058629491,1621,4251,5831,7662,0892,304
Borrowings 2827000000533420247157156
Other Liabilities 11913411895128145341415309297357383415
Total Liabilities 3524756256909161,0911,3741,6612,3492,3832,4542,7132,959
Fixed Assets 1401501661522082094134471,3751,3051,2281,1681,232
CWIP 0141810311101556317
Investments 938641061451851645965150114327486
Other Assets 2032863914145546947861,1448939231,1071,2151,225
Total Assets 3524756256909161,0911,3741,6612,3492,3832,4542,7132,959

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 98122159171197219284398447456535569
Cash from Investing Activity + -89-113-163-137-172-100-26-212-449-287-24-303
Cash from Financing Activity + -10-10-3213-55-190-139136-283-414-334
Net Cash Flow -28-5237646748134-11497-68
Free Cash Flow 6687115120125177205339-28412479516
CFO/OP 107%112%108%102%110%110%110%115%103%115%110%105%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow111.00129.00210.00238.00264.00294.00344.00436.0028.0070.00362.00541.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 161717171416141515131313
Inventory Days 3731334440703938283027
Days Payable 908997106111144132107127151151
Cash Conversion Cycle 16-35-42-47-47-55-60-78-54-87-108-110
Working Capital Days -26-92719170-19-17-54-56-46-30
ROCE %60%48%47%43%38%35%32%33%29%18%25%29%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 55.03%55.01%54.61%54.60%54.60%54.60%53.92%53.91%53.91%53.79%53.21%53.21%
FIIs 24.89%23.27%24.35%25.36%26.15%25.43%26.82%26.82%23.90%21.69%21.86%20.29%
DIIs 6.56%8.34%8.85%9.27%9.40%12.42%12.60%12.88%15.79%17.62%18.22%19.20%
Government 0.00%0.29%0.29%0.29%0.29%0.29%0.29%0.29%0.29%0.29%0.27%0.01%
Public 13.01%12.65%11.48%10.12%9.24%6.95%6.02%5.82%5.84%6.22%6.07%6.94%
Others 0.51%0.44%0.41%0.37%0.32%0.30%0.33%0.28%0.27%0.39%0.37%0.35%
No. of Shareholders 1,80,1631,74,4441,60,6791,49,9011,46,7411,31,1891,16,6061,16,2361,15,6991,18,6561,12,7031,16,167

Shareholding Pattern Chart

No. of Shareholders

Dr Lal Pathlabs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Flexi Cap Fund 4,000,000 0.58 563.82,000,0002026-01-26 06:37:47100%
UTI Flexi Cap Fund 2,560,250 1.53 360.872,401,2522026-02-23 00:55:506.62%
Aditya Birla Sun Life Flexi Cap Fund 1,668,560 0.95 235.18823,0072026-01-26 06:37:47102.74%
Nippon India Multi Cap Fund 1,416,484 0.41 199.651,302,3072026-02-23 00:55:508.77%
SBI Large & Midcap Fund 1,300,000 0.49 183.24650,0002026-01-26 06:37:47100%
Nippon India Small Cap Fund 1,290,970 0.28 181.96645,4852026-01-26 06:37:47100%
Nippon India Pharma Fund 1,218,224 2.18 171.71609,1122026-01-26 06:37:47100%
HDFC ELSS Tax Saver Fund 1,140,000 0.96 160.68570,0002026-01-26 06:37:47100%
Sundaram Mid Cap Fund 1,054,917 1.15 148.69519,3512026-01-26 06:37:47103.12%
UTI Mid Cap Fund 781,126 0.96 110.1390,5632026-01-26 06:37:47100%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 58.4843.0528.8241.7035.33
Diluted EPS (Rs.) 58.4042.9828.7441.7035.25
Cash EPS (Rs.) 75.8660.6046.9355.0044.83
Book Value[Excl.RevalReserv]/Share (Rs.) 259.92225.85203.86185.20153.10
Book Value[Incl.RevalReserv]/Share (Rs.) 259.92225.85203.86185.20153.10
Revenue From Operations / Share (Rs.) 294.45266.73241.93250.45189.72
PBDIT / Share (Rs.) 94.3981.2763.7673.5858.51
PBIT / Share (Rs.) 77.4164.0645.7460.6149.24
PBT / Share (Rs.) 74.7460.5541.2456.9947.32
Net Profit / Share (Rs.) 58.8943.4028.9242.0335.57
NP After MI And SOA / Share (Rs.) 58.2742.8528.6541.3734.99
PBDIT Margin (%) 32.0530.4626.3529.3730.83
PBIT Margin (%) 26.2924.0118.9024.2025.95
PBT Margin (%) 25.3822.7017.0422.7524.94
Net Profit Margin (%) 19.9916.2711.9516.7818.74
NP After MI And SOA Margin (%) 19.7916.0611.8416.5118.44
Return on Networth / Equity (%) 22.4219.3414.3322.8623.42
Return on Capital Employeed (%) 27.9526.8619.9027.2529.58
Return On Assets (%) 17.9314.5610.0114.6517.55
Long Term Debt / Equity (X) 0.000.000.050.110.00
Total Debt / Equity (X) 0.000.040.140.220.00
Asset Turnover Ratio (%) 0.950.910.850.961.01
Current Ratio (X) 3.392.422.071.754.18
Quick Ratio (X) 3.302.342.001.654.02
Inventory Turnover Ratio (X) 67.030.000.000.000.00
Dividend Payout Ratio (NP) (%) 41.0355.7641.6233.5533.98
Dividend Payout Ratio (CP) (%) 31.7739.7825.5525.5426.87
Earning Retention Ratio (%) 58.9744.2458.3866.4566.02
Cash Earning Retention Ratio (%) 68.2360.2274.4574.4673.13
Interest Coverage Ratio (X) 35.3723.1114.1620.3230.47
Interest Coverage Ratio (Post Tax) (X) 23.0713.347.4212.6119.53
Enterprise Value (Cr.) 19910.0218177.2514843.3421493.2321670.29
EV / Net Operating Revenue (X) 8.098.167.3610.3013.70
EV / EBITDA (X) 25.2326.7927.9235.0544.44
MarketCap / Net Operating Revenue (X) 8.428.487.5610.4114.27
Retention Ratios (%) 58.9644.2358.3766.4466.01
Price / BV (X) 9.5310.219.1514.4118.12
Price / Net Operating Revenue (X) 8.428.487.5610.4114.27
EarningsYield 0.020.010.010.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Dr. Lal Pathlabs Ltd. is a Public Limited Listed company incorporated on 14/02/1995 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L74899DL1995PLC065388 and registration number is 065388. Currently Company is involved in the business activities of Other human health activities. Company's Total Operating Revenue is Rs. 2351.62 Cr. and Equity Capital is Rs. 83.59 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Hospitals & Medical ServicesBlock E, New Delhi Delhi 110085Contact not found
Management
NamePosition Held
Brig.(Hony) Dr. Arvind LalExecutive Chairman
Dr. Vandana LalWhole Time Director
Dr. Archana Lal ErdmannNon Executive Director
Mr. Rahul SharmaNon Executive Director
Mr. Arun DuggalIndependent Director
Mr. Gurinder Singh KalraIndependent Director
Mr. Rajit MehtaIndependent Director
Mrs. Somya SatsangiIndependent Director
Mr. Rohit BhasinIndependent Director

FAQ

What is the intrinsic value of Dr Lal Pathlabs Ltd and is it undervalued?

As of 10 April 2026, Dr Lal Pathlabs Ltd's intrinsic value is ₹532.25, which is 59.80% lower than the current market price of ₹1,324.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (24.3 %), book value (₹143), dividend yield (0.91 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Dr Lal Pathlabs Ltd?

Dr Lal Pathlabs Ltd is trading at ₹1,324.00 as of 10 April 2026, with a FY2026-2027 high of ₹1,771 and low of ₹1,176. The stock is currently near its 52-week low. Market cap stands at ₹22,178 Cr..

How does Dr Lal Pathlabs Ltd's P/E ratio compare to its industry?

Dr Lal Pathlabs Ltd has a P/E ratio of 40.4, which is below the industry average of 75.17. This is broadly in line with or below the industry average.

Is Dr Lal Pathlabs Ltd financially healthy?

Key indicators for Dr Lal Pathlabs Ltd: ROCE of 28.9 % indicates efficient capital utilization; ROE of 24.3 % shows strong shareholder returns. Dividend yield is 0.91 %.

Is Dr Lal Pathlabs Ltd profitable and how is the profit trend?

Dr Lal Pathlabs Ltd reported a net profit of ₹492 Cr in Mar 2025 on revenue of ₹2,461 Cr. Compared to ₹350 Cr in Mar 2022, the net profit shows an improving trend.

Does Dr Lal Pathlabs Ltd pay dividends?

Dr Lal Pathlabs Ltd has a dividend yield of 0.91 % at the current price of ₹1,324.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Dr Lal Pathlabs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports